Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support... see more

PINL:GRPOF - Post Discussion

Traxion Sab De Cv Ord Shs > Not valued properly
View:
Post by Golddetector on Mar 29, 2021 6:31pm

Not valued properly

I think this company is not valued properly by investors. I did a bit of digging and went back few years to get full picture and I think guy has a good case here. Tbp is pharmaceutical not cannabis company. It is developing drug to Canadian and USA standards which is very costly. To bring it to phase two typically this worth 250 millions per drug depend on the potential. Completing stage 3 is a 1.2 billions on average. They spent years and years researching this so it has a very good chance of success. Anyway this can not go under the radar for long. Listen to the 1st video with jack and check the key points and do your dd and do not only take guy or jacks word for it. Imo this should be 750 million to 1 billion company or 3 to 5 at this stage. If the drugs pass phase 3 it will be valued in billions. Jmo. I know some ppl here disagree with this. I bought some shares and will add more as we go. Do your own dd and good luck longs.
Comment by endpntplay on Mar 29, 2021 7:37pm
This company is OVERVALUED. They should be valued at CASH only. 
Comment by Realnewsalways1 on Mar 30, 2021 11:16am
This post has been removed in accordance with Community Policy
Comment by Realnewsalways1 on Apr 01, 2021 4:27am
Hey if you dont like this stock which you dont .....then leave instead of making uneducated remarks that  mean absolutely nothing...nothing
Comment by SamV21 on Apr 01, 2021 6:06pm
Perhaps not... did some research and it appears that bio research companies are valued much different than other companies.You have to look really at potenial and as a company progresses through different stages or phases of a drug research the percentage of it becoming a presciption drug decreases only about 15% ever make it to maket, we are talking billions investested in a 15% chance.Because ...more  
Comment by SamV21 on Mar 29, 2021 10:57pm
Thanks for your input. It just doesn,t seem they have the capital / deep pockets to obtain their dreams.The drug Dronabinol has been around for years had FDA approval in 2017 and they make it sound like they discovered it.If they had their ducks in a row the other big Pharma companies would be knocking at their door. Awaye is a pain creme Tetra Bio Pharma but it is priced out of the market.Drs ...more  
Comment by Realnewsalways1 on Mar 30, 2021 11:13am
Thoughtful and pragmatic comments on status and opportunity
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities